Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cardio Diagnostics Holdings Inc (CDIO)
| -31.9 | 18.3 | -13.4 | -51.6 | -51.5 | -- | -- |
|
BSE Sensex
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Cardio Diagnostics Holdings Inc (CDIO)
| -90.1 | -62.9 | 134.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Cardio Diagnostics Holdings Inc (CDIO)
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test... targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois. Read more
-
Co-Founder, CEO & Director
Dr. Meeshanthini V. Dogan Ph.D.
-
Co-Founder, CEO & Director
Dr. Meeshanthini V. Dogan Ph.D.
-
Headquarters
Chicago, IL
-
Website
FAQs for Cardio Diagnostics Holdings Inc (CDIO)
What is the current share price of Cardio Diagnostics Holdings Inc (CDIO) Today?
The share price of Cardio Diagnostics Holdings Inc (CDIO) is $1.85 (NASDAQ) as of 02-Sep-2026 14:33 EDT. Cardio Diagnostics Holdings Inc (CDIO) has given a return of -51.53% in the last 3 years.
What is the current PB & PE ratio of Cardio Diagnostics Holdings Inc (CDIO)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.76 |
0.71 |
2024 |
-5.03 |
4.41 |
2023 |
-6.11 |
17.29 |
2022 |
-2.16 |
2.34 |
2021 |
-- |
-- |
What is the 52 Week High and Low of Cardio Diagnostics Holdings Inc (CDIO)?
The 52-week high and low of Cardio Diagnostics Holdings Inc (CDIO) are Rs 7.91 and Rs 1.05 as of 03-Sep-2026.
What is the market cap of Cardio Diagnostics Holdings Inc (CDIO)?
Cardio Diagnostics Holdings Inc (CDIO) has a market capitalisation of $ 5 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cardio Diagnostics Holdings Inc (CDIO)?
Before investing in Cardio Diagnostics Holdings Inc (CDIO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.